Revised Final Guidance on Nitrosamines Offers New Recommendations for Assessment and Control
FDA Law Blog
SEPTEMBER 11, 2024
Nitrosamines are impurities that can form during drug manufacturing and are considered potentially potent carcinogens. It’s these varied scenarios that give quality managers nightmares. FDA recognizes that nitrosamine detection and remediation are complicated undertakings for quality managers.
Let's personalize your content